IN2013MU02911A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02911A
IN2013MU02911A IN2911MU2013A IN2013MU02911A IN 2013MU02911 A IN2013MU02911 A IN 2013MU02911A IN 2911MU2013 A IN2911MU2013 A IN 2911MU2013A IN 2013MU02911 A IN2013MU02911 A IN 2013MU02911A
Authority
IN
India
Prior art keywords
relates
pharmaceutical compositions
sodium picosulfate
citric acid
magnesium oxide
Prior art date
Application number
Other languages
English (en)
Inventor
Muthaiyyan Essakimuthu Kannan
Jitendra Rameshchandra Patel
Paritosh Kunwar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN2911MU2013 priority Critical patent/IN2013MU02911A/en
Priority to US14/482,678 priority patent/US20150072014A1/en
Publication of IN2013MU02911A publication Critical patent/IN2013MU02911A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
IN2911MU2013 2013-09-10 2013-09-10 IN2013MU02911A (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN2911MU2013 IN2013MU02911A (fr) 2013-09-10 2013-09-10
US14/482,678 US20150072014A1 (en) 2013-09-10 2014-09-10 Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2911MU2013 IN2013MU02911A (fr) 2013-09-10 2013-09-10

Publications (1)

Publication Number Publication Date
IN2013MU02911A true IN2013MU02911A (fr) 2015-07-03

Family

ID=52625867

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2911MU2013 IN2013MU02911A (fr) 2013-09-10 2013-09-10

Country Status (2)

Country Link
US (1) US20150072014A1 (fr)
IN (1) IN2013MU02911A (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
US20160220492A1 (en) * 2015-01-31 2016-08-04 Gavis Pharmaceuticals Pharmaceutical composition of sodium picosulfate
CN109310774A (zh) * 2015-08-17 2019-02-05 费林股份公司 含有匹可硫酸盐和柠檬酸镁的液体制剂
CN105456264B (zh) * 2015-12-03 2018-07-10 广州瑞尔医药科技有限公司 双效缓泻的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7961094A (en) * 1993-10-19 1995-05-08 Procter & Gamble Company, The Picosulphate dosage form
PL2207526T3 (pl) * 2007-10-12 2018-06-29 Ferring International Center S.A. Sposób wytwarzania produktu farmaceutycznego zawierającego kwas cytrynowy, tlenek magnezu, wodorowęglan potasu i pikosiarczan sodu, kompozycja farmaceutyczna zawierająca granulki otrzymane takim sposobem i jego produkty pośrednie
HUE043852T2 (hu) * 2012-07-27 2019-09-30 Redhill Biopharma Ltd A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei

Also Published As

Publication number Publication date
US20150072014A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX366899B (es) Nuevos compuestos.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
PH12014501991B1 (en) Phenicol antibacterials
IN2015DN03327A (fr)
IN2013MU03583A (fr)
TN2012000457A1 (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
PL2841549T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
PL2841548T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
PL2961822T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
IN2013MU03373A (fr)
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
IN2013MU02911A (fr)
EP2983684B8 (fr) Huile essentielle et aloès pour le traitement et la prophylaxie d'inflammations provoquées par demodex, notamment la blépharite marginale, composition pharmaceutique contenant une huile essentielle et/ou de l'aloès et utilisation de l'huile essentielle et de l'aloès et de leurs compositions pour la production d'une préparation utilisée dans le traitement et la prophylaxie des inflammations mentionnées
WO2015044434A3 (fr) Fluoro-9-méthyl-β-carboline
GB2527233A (en) Composition comprising hydrocortisone
MY168952A (en) Fe (iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
WO2014122671A3 (fr) Compositions orales solides de saxagliptine